论文部分内容阅读
目的 评估对滋养细胞肿瘤肝转移患者的治疗方法及其临床预后。方法 回顾性分析 1985～ 1998年收治的滋养细胞肿瘤肝转移患者 16例。所有患者均接受以 5 -氟尿嘧啶 (5 - FU)为主的联合化疗或 EMA/ CO(氨甲蝶呤、更生霉素、足叶乙甙 /长春新碱、环磷酰胺 )化疗 ,其中 8例进行选择性肝动脉插管局部灌注化疗 ,通过监测血β-人绒毛膜促性腺激素 (β- HCG)水平 ,超声及 CT等检查判断治疗效果。结果 16例患者经以上治疗 4例完全缓解 ,2例血生化指标缓解带瘤存活 ,10例死亡 ,存活率为 37.5 % (6 / 16 )。结论 滋养细胞肿瘤肝转移预后较差。早期诊断与及时的多药、多途径联合化疗是改善其治疗效果的重要环节。
Objective To evaluate the treatment and prognosis of patients with liver metastasis of trophoblastic tumor. Methods Retrospective analysis of 16 cases of liver metastasis of trophoblastic tumor from 1985 to 1998. All patients received chemotherapy combined with 5 - fluorouracil (5 - FU) or EMA / CO (methotrexate, dactinomycin, etoposide / vincristine, cyclophosphamide) chemotherapy, of which 8 Selective hepatic artery perfusion chemotherapy, by monitoring the level of β-human chorionic gonadotropin (β-HCG), ultrasound and CT examination to determine the treatment effect. Results In the 16 patients, the complete remission was achieved in 4 cases. The blood biochemical indexes were relieved in 2 cases and the survival rate was 37.5% (6/16) in 10 cases. Conclusion Trophoblastic tumor liver metastasis prognosis is poor. Early diagnosis and timely multi-drug, multi-channel combination chemotherapy is to improve the treatment of an important part.